Fig. 6

In vivo therapeutic efficacy study. A Time-course changes of the proportion of hCD45⁺ cells in the peripheral blood of AML-PDX mice subjected to different treatments. Proportion of hCD45⁺ cells in B spleen and C bone marrow at the end of treatments. D H&E and immunohistochemical staining of the spleen tissue harvested at the end of treatments. Human AML cells were identified with anti-hCD45 antibody (brown area labeled “L”). Scale bars, 200 μm. E Spleen-to-body weight ratios of different treatment groups at the 4-week endpoint. F High-magnification images of H&E and immunohistochemical staining of the bone marrow specimen. AML cells were identified with anti-hCD45 antibody (brown area labeled “L”). Scale bars, 100 μm. G Survival curves of AML-PDX mice subjected to different treatments; ^*P < 0.05; ^**P < 0.005; ^***P < 0.0005; n.s.: nonsignificant